Emerging anti-spike monoclonal antibodies against SARS-CoV-2.
Eloy E OrdayaRaymund R RazonablePublished in: Expert opinion on biological therapy (2024)
Although the available data of novel mAbs holds promise, we anticipate that these agents will face similar challenges as encountered by prior authorized agents, which is the continued evolution of SARS-CoV-2 and the emergence of new escape mutations. Strategies to potentially mitigate this are discussed. Based on prior successful experience, immunocompromised patients will certainly benefit from the utilization of mAbs for the prevention and treatment of COVID-19; thus, we need to design potential interventions to ensure the sustained activity of these agents.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- ejection fraction
- coronavirus disease
- newly diagnosed
- big data
- physical activity
- prognostic factors
- electronic health record
- machine learning
- risk assessment
- combination therapy
- deep learning
- chronic kidney disease
- human health
- extracorporeal membrane oxygenation
- respiratory failure